A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.

ABSTRACT: Novel chemotherapeutics with marked and selective antitumor activity are essential to develop, particularly those that can overcome resistance to established therapies. Iron (Fe) is critical for cell-cycle progression and DNA synthesis and potentially represents a novel molecular target for the design of new anticancer agents. The aim of this study was to evaluate the antitumor activity and Fe chelation efficacy of a new class of Fe chelators using human tumors. In this investigation, the ligands showed broad antitumor activity and could overcome resistance to established antitumor agents. The in vivo efficacy of the most effective chelator identified, di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT), was assessed by using a panel of human xenografts in nude mice. After 7 week

SUBMITTER: Whitnall M 

PROVIDER: S-EPMC1595448 | biostudies-literature | 2006 Oct

REPOSITORIES: biostudies-literature